Mega Contracts Monitor ($100M+) — August 09, 2026

SIGA Technologies won a $626.5 million firm-fixed-price contract from HHS/BARDA for smallpox antiviral drug development and procurement, with $447.2 million already outlayed. This provides approximately $56.9 million in annual revenue visibility through 2029, reinforcing SIGA's position in biodefense.

QTC Medical Services, a Leidos subsidiary, received a $209.2 million firm-fixed-price delivery order from the VA for disability exams in the Southeast region. The contract was performed over one year (FY2021) and is now fully executed, with $196.6 million outlayed, limiting forward growth visibility.

OUR RESCUE, a nonprofit, received a $158.1 million non-competed time-and-materials contract from HHS for legal support services, with a potential total of $244 million if all options are exercised. The short 6-month base period and sole-source nature create uncertainty.

OUR RESCUE's $158.1M time-and-materials contract carries execution risk due to cost overrun potential and the nonprofit's capacity to manage a $158M obligation. The 6-month base period increases renewal uncertainty.

SIGA Technologies derives a significant portion of its revenue from this single $626.5M HHS contract. Any termination, funding cut, or protest could materially impact SIGA's financials.

The VA's $209.2M medical exam contract for Leidos is fully executed with no follow-on identified. A shift in VA disability processing priorities or budget cuts could reduce future awards.

SIGA Technologies' $626.5M contract provides a multi-year revenue base through 2029. Option exercises or modifications could increase total value, and BARDA's continued biodefense focus may lead to follow-on antiviral contracts.

OUR RESCUE's $158.1M HHS bridge contract could expand to $244M if all options are exercised. The non-competed nature suggests HHS values the relationship, potentially leading to further sole-source awards.

Leidos' completed VA contract demonstrates capability in medical disability exams. The VA's ongoing need for such services could lead to new competitive awards in other regions, especially if claims volume rises.

Two of three contracts ($784.6M total) are from HHS, covering biodefense R&D (SIGA) and legal support (OUR RESCUE). This underscores HHS's dual focus on pandemic preparedness and administrative continuity, even amid budget uncertainty.

Leidos' $209.2M VA contract is fully executed, reflecting steady demand for disability exams. However, the one-year term and full competition suggest limited pricing power and growth visibility.

{"entity" => "SIGA Technologies", "reason" => "Holds a $626.5M HHS contract through 2029; any funding cuts or protests could materially impact revenue.", "trigger" => "NDAA passage with biodefense funding levels, BARDA budget announcement, option exercise"}

{"entity" => "OUR RESCUE", "reason" => "Nonprofit with $158.1M HHS bridge contract; option exercise by February 2027 is critical for revenue continuity.", "trigger" => "February 2027 option exercise deadline, HHS legal services RFP release"}

{"entity" => "Leidos Holdings", "reason" => "VA contract fully executed; follow-on awards depend on new VA solicitations and disability claims volume.", "trigger" => "VA solicitation for medical disability exams, claims backlog data release"}